MedDRA preferred term

Infective pulmonary exacerbation of cystic fibrosis: adverse event reports recording this term

5,413 reports to FDA record it, 2010–2026; 0% of the database.

Read first · FDA's statement on these data

Adverse event reports submitted to FDA do not undergo extensive validation or verification. Therefore, a causal relationship cannot be established between product and reactions listed in a report. While a suspected relationship may exist, it is not medically validated and should not be the sole source of information for clinical decision making or other assumptions about the safety or efficacy of a product. Additionally, it is important to remember that adverse event reports represent a small percentage of total usage numbers of a product. Common products may have a higher number of adverse events due to the higher total number of people using the product. openFDA, FDA

FDA adds: "There is no certainty that the reported event (adverse event or medication error) was actually due to the product. FDA does not require that a causal relationship between a product and event be proven, and reports do not always contain enough detail to properly evaluate an event." The information in these reports "cannot be used to estimate the incidence of these events."

Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated.

Not medical advice. This site counts what was reported to FDA. Questions about a medicine or device belong with a pharmacist or clinician.

5,413
reports recording the term: 0% of all reports; 167
reports, 12 months to June 2026: 169 in the 12 months before; 87%
marked serious by the reporter: 57.4% across all reports; 2.3%
record death among outcomes, as reported: 9.1% across all reports

"Infective pulmonary exacerbation of cystic fibrosis" is a MedDRA preferred term recorded in 5,413 adverse event reports received by FDA, 0% of the database, from November 2010 to June 2026. The term is chosen by whoever codes the report to match what the reporter described.

167 reports recorded it in the 12 months to June 2026, close to the 169 of the 12 months before. FDA releases FAERS data quarterly, so the newest months are incomplete and grow in later releases. Of reports recording this term, 87% are marked serious, 2.3% include death among the outcomes and 80.9% include hospitalisation, as reported.

The drugs listed most often as suspect products in those reports are Orkambi, Symdeko and Trikafta. That order mostly follows how many reports each drug has overall; the table also gives the term's share within each drug's own reports. FDA states that "a causal relationship cannot be established between product and reactions listed in a report" and that for any given report "there is no certainty that a suspected drug caused the event."

Reports by month, five years

FDA releases FAERS data quarterly, so the newest months are incomplete and grow in later releases.

Drugs listed as suspect products in these reports

Drug	Class	Reports with this term	Share of the drug's own reports
Orkambi	Cystic fibrosis transmembrane conductance regulator potentiator	1,412	17.4%
Symdeko	—	1,162	23.7%
Trikafta	—	723	6.7%
Kalydeco	Cystic fibrosis transmembrane conductance regulator potentiator	532	7.5%
Aztreonam Lysine	—	421	3.4%
Pulmozyme	—	250	4.4%
Tobi	Aminoglycoside antibacterial	211	5.7%
TOBI Podhaler	Aminoglycoside antibacterial	186	7%
Bethkis	Aminoglycoside antibacterial	125	6.5%
Tobramycin	Aminoglycoside antibacterial	117	2.4%
Cayston	—	104	8.5%
Elexacaftor Ivacaftor Tezacaftor	—	96	2.7%
Kitabis Pak	Aminoglycoside antibacterial	58	8.8%
Vx-770	—	58	13.7%
Ivacaftor	Cystic fibrosis transmembrane conductance regulator potentiator	52	12.1%
Symkevi	—	34	9.7%
Xolair	Anti-IgE	25	0%
Arikayce	Aminoglycoside antibacterial	23	0.4%
Ciprofloxacin	Fluoroquinolone antibacterial	23	0.1%
Alyftrek	Cystic fibrosis transmembrane conductance regulator potentiator	22	3.6%
Creon	—	20	0.1%
Azithromycin Anhydrous	—	18	0.1%
Prednisone	Corticosteroid	18	0%
Dupixent	Interleukin-4 receptor alpha antagonist	17	0%
Salbutamol	—	15	0.2%

Drugs with a page on this site, ordered by the number of their reports recording this term. The last column is the term's share within that drug's own reports, against 0% across the whole database. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic."

By pharmacologic class

Class	Reports with this term	Share of class reports	Median drug in class
Cystic fibrosis transmembrane conductance regulator potentiator	1,966	12.5%	7.5%
Aminoglycoside antibacterial	725	1.9%	0%
Anti-IgE	37	0%	0%
Corticosteroid	35	0%	0%
Fluoroquinolone antibacterial	23	0%	0%
beta2-Adrenergic agonist	18	0%	0%
Interleukin-4 receptor alpha antagonist	17	0%	0%
Cephalosporin antibacterial	15	0%	0%
Antimycobacterial	14	0.1%	0%
Leukotriene receptor antagonist	13	0%	0%

Classes ordered by count. Class shares follow the class's overall report volume as much as anything else.

Patients in these reports

Patient age

Under 20.3%15

2 to 118%433

12 to 1713.3%721

18 to 4439.3%2,127

45 to 645.3%286

65 to 740.9%50

75 and over0.1%7

Age not given32.8%1,774

Patient sex

Female54.8%2,967

Male39.4%2,135

Not given5.7%311

Grey bar: all 20,646,523 reports in the database. 88% of these reports give the United States as the country.

Questions about "Infective pulmonary exacerbation of cystic fibrosis"

What does "Infective pulmonary exacerbation of cystic fibrosis" mean in an adverse event report?

It is a MedDRA preferred term, the dictionary FDA uses to code what a reporter described. The report's own description is not published by openFDA and is not shown here.

How many reports record infective pulmonary exacerbation of cystic fibrosis?

5,413 reports through June 2026 (0% of all reports), 167 of them in the latest 12 months.

Which drugs appear most often in these reports?

Orkambi (1,412), Symdeko (1,162), Trikafta (723), Kalydeco (532) and Aztreonam Lysine (421). Drugs with many reports overall lead almost every term's list. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic."

Does a drug appearing here mean it was responsible for this reaction?

No. FDA states that "a causal relationship cannot be established between product and reactions listed in a report" and that for any given report "there is no certainty that a suspected drug caused the event."

I have this symptom. What should I do?

This site cannot assess anyone. A pharmacist or clinician can; for an emergency, call the local emergency number. Nothing on this page is medical advice.

Where this comes from. Counts are built from the openFDA Drug Adverse Event (FAERS) bulk export released 28 Sep 2026, which holds reports FDA received through 30 Jun 2026. Drug names are as reported, resolved to the brand or generic name on the FDA label where openFDA's harmonisation matched them; classes are the pharmacologic class (EPC) from the label and the National Drug Code Directory of 17 Sep 2026. Terms are pooled across spelling and capitalisation variants of one MedDRA preferred term. No report narrative, lot number, patient detail or reporter identity is published. See the methodology and sources; FDA's record is authoritative, and corrections are handled within five working days.

Drug data (FAERS) through 30 Jun 2026; device data (MAUDE) through 31 Aug 2026. Not medical advice.